Rivaroxaban in patients with cancer-associated thromboembolism
Thieme. All rights reserved..
This review article describes insights into the prevention and treatment of cancer-associated venous thromboembolism (VTE) with direct factor Xa inhibitors (FXaI) and refers in particular to the CALLISTO study program with rivaroxaban. CALLISTO includes randomized clinical trials on different topics as well as real-world evidence.Prevention and treatment of cancer-associated VTE have so far relied on low molecular weight heparins (LMWH). Meanwhile, randomized controlled trials have found comparable to superior efficacy of FXaI vs. LMWH, and the findings are now being incorporated into recommendations and guidelines. A possibly increased risk of bleeding, especially in patients with unresected gastrointestinal or urogenital tumors, should be considered. This was first observed during therapy with FXaI but can also affect LMWH. The selection of suitable patients and the optimization of treatment pathways are therefore of great importance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
Deutsche medizinische Wochenschrift (1946) - 147(2022), 23 vom: 06. Nov., Seite 1545-1551 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Rivaroxaban bei tumorassoziierter venöser Thromboembolie |
|---|
| Beteiligte Personen: |
Bauersachs, Rupert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NDF7JZ4M3 |
|---|
| Anmerkungen: |
Date Completed 21.11.2022 Date Revised 06.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1933-1391 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348975325 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348975325 | ||
| 003 | DE-627 | ||
| 005 | 20231226041546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-1933-1391 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM348975325 | ||
| 035 | |a (NLM)36384156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Bauersachs, Rupert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rivaroxaban in patients with cancer-associated thromboembolism |
| 246 | 3 | 3 | |a Rivaroxaban bei tumorassoziierter venöser Thromboembolie |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2022 | ||
| 500 | |a Date Revised 06.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a This review article describes insights into the prevention and treatment of cancer-associated venous thromboembolism (VTE) with direct factor Xa inhibitors (FXaI) and refers in particular to the CALLISTO study program with rivaroxaban. CALLISTO includes randomized clinical trials on different topics as well as real-world evidence.Prevention and treatment of cancer-associated VTE have so far relied on low molecular weight heparins (LMWH). Meanwhile, randomized controlled trials have found comparable to superior efficacy of FXaI vs. LMWH, and the findings are now being incorporated into recommendations and guidelines. A possibly increased risk of bleeding, especially in patients with unresected gastrointestinal or urogenital tumors, should be considered. This was first observed during therapy with FXaI but can also affect LMWH. The selection of suitable patients and the optimization of treatment pathways are therefore of great importance | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 700 | 1 | |a Voigtländer, Minna |e verfasserin |4 aut | |
| 700 | 1 | |a Langer, Florian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Deutsche medizinische Wochenschrift (1946) |d 1946 |g 147(2022), 23 vom: 06. Nov., Seite 1545-1551 |w (DE-627)NLM000002852 |x 1439-4413 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2022 |g number:23 |g day:06 |g month:11 |g pages:1545-1551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1933-1391 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2022 |e 23 |b 06 |c 11 |h 1545-1551 | ||